JP7389749B2 - プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法 - Google Patents

プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法 Download PDF

Info

Publication number
JP7389749B2
JP7389749B2 JP2020544425A JP2020544425A JP7389749B2 JP 7389749 B2 JP7389749 B2 JP 7389749B2 JP 2020544425 A JP2020544425 A JP 2020544425A JP 2020544425 A JP2020544425 A JP 2020544425A JP 7389749 B2 JP7389749 B2 JP 7389749B2
Authority
JP
Japan
Prior art keywords
certain embodiments
alkyl
substituted
formula
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514955A5 (enExample
JP2021514955A (ja
Inventor
ジュン チー
ヤン ソン
ダーミンダー チャウハン
レイ ウー
ケネス シー． アンダーソン
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2021514955A publication Critical patent/JP2021514955A/ja
Publication of JP2021514955A5 publication Critical patent/JP2021514955A5/ja
Application granted granted Critical
Publication of JP7389749B2 publication Critical patent/JP7389749B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020544425A 2018-02-23 2019-02-22 プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法 Active JP7389749B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634632P 2018-02-23 2018-02-23
US62/634,632 2018-02-23
PCT/US2019/019162 WO2019165216A1 (en) 2018-02-23 2019-02-22 Small molecules that block proteasome-associated ubiquitin receptor rpn13 function and uses thereof

Publications (3)

Publication Number Publication Date
JP2021514955A JP2021514955A (ja) 2021-06-17
JP2021514955A5 JP2021514955A5 (enExample) 2023-08-21
JP7389749B2 true JP7389749B2 (ja) 2023-11-30

Family

ID=65724533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544425A Active JP7389749B2 (ja) 2018-02-23 2019-02-22 プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法

Country Status (6)

Country Link
US (1) US11702402B2 (enExample)
EP (1) EP3755377A1 (enExample)
JP (1) JP7389749B2 (enExample)
AU (1) AU2019224089B2 (enExample)
CA (1) CA3090414A1 (enExample)
WO (1) WO2019165216A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
AU2021264869B2 (en) * 2020-04-29 2025-09-11 Onegene Biotechnology Inc. Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes
EP4323340A2 (en) 2021-04-13 2024-02-21 President and Fellows of Harvard College E3 ligase binders and uses thereof
CN115260212B (zh) * 2022-08-01 2023-05-23 桂林医学院 3,5-双(亚苄基)-4-哌啶酮衍生物及其制备方法和应用
US20250137057A1 (en) * 2023-10-26 2025-05-01 The Chinese University Of Hong Kong Adrm1/rpn13 spliced variant in the prognosis and treatment of hepatocellular carcinoma
WO2025207482A1 (en) * 2024-03-25 2025-10-02 Augusta University Research Institute, Inc. Diarylpiperidone hybrid conjugates and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106725A1 (en) 2013-05-08 2016-04-21 The Johns Hopkins University Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity
JP2017513862A (ja) 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106725A1 (en) 2013-05-08 2016-04-21 The Johns Hopkins University Novel bis-Benzylidine Piperidone Proteasome Inhibitor with Anticancer Activity
JP2017513862A (ja) 2014-04-14 2017-06-01 アルビナス インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法

Also Published As

Publication number Publication date
WO2019165216A1 (en) 2019-08-29
AU2019224089A1 (en) 2020-08-13
US11702402B2 (en) 2023-07-18
JP2021514955A (ja) 2021-06-17
US20210130324A1 (en) 2021-05-06
AU2019224089B2 (en) 2024-10-10
CA3090414A1 (en) 2019-08-29
EP3755377A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
EP3544970B1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
JP2021514958A (ja) 選択的なタンパク質分解を誘導するための低分子およびその使用法
EP3341007B1 (en) Malt1 inhibitors and uses thereof
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
AU2020301399B2 (en) HCK degraders and uses thereof
US11702402B2 (en) Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
EP3416950A1 (en) Max binders as myc modulators and uses thereof
AU2020205665C1 (en) DOT1L degraders and uses thereof
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
HK1245260B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200918

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201026

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231117

R150 Certificate of patent or registration of utility model

Ref document number: 7389749

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150